Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trasylol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Trasylol (Aprotinin, BAYA0128) | DRUG | A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump |
| Placebo | DRUG | A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump |
Inclusion Criteria: * Subjects requiring elective primary total hip replacement surgery * Documented, signed, dated informed consent obtained prior to any study specific procedures being performed Exclusion Criteria: * Subjects with previous exposure to aprotinin in the last 6 months. If the subj...
Trasylol is used to reduce blood loss and transfusion requirements in patients undergoing elective primary total hip replacement surgery. It is a small molecule drug being developed by Bayer AG for the therapeutic area of blood loss and surgical indications.
Trasylol is being developed by Bayer AG, a pharmaceutical company listed on the stock exchange under the ticker BAYRY. The drug is currently in Phase 3 clinical development for reducing blood loss during surgical procedures.
Trasylol is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its ability to reduce blood loss and transfusion needs in patients undergoing elective primary total hip replacement.
Trasylol has one completed Phase 3 clinical trial registered under NCT00668031. This trial, titled 'Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement,' enrolled 359 participants across the United States, Canada, and Puerto Rico.
Trasylol is the brand name for aprotinin, a small molecule drug. The clinical trial NCT00668031 specifically evaluates the effect of aprotinin on transfusion requirements and blood loss, confirming that Trasylol and aprotinin refer to the same active substance.